Latest Ratios: P/E Ratio 1.1x · EV/EBITDA -14.0x · ROE 9.8%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $14M | $22M | $18M | $34M | $28M | $30M | $164M | — | — |
| Enterprise Value | $-153261843 | $-1117992126 | $-1090045880 | $-1176288658 | $-1012880680 | $-791253440 | $-691016768 | — | — |
| P/E Ratio → | 1.09 | 0.24 | 0.19 | 0.19 | 0.26 | — | — | — | — |
| P/S Ratio | 0.12 | 0.03 | 0.02 | 0.03 | 0.03 | 0.03 | 0.31 | — | — |
| P/B Ratio | 0.10 | 0.02 | 0.02 | 0.04 | 0.04 | 0.05 | 0.26 | — | — |
| P/FCF | 2.17 | 0.50 | 0.36 | 0.20 | 0.02 | 5.03 | 0.79 | — | — |
| P/OCF | 1.96 | 0.45 | 0.31 | 0.20 | 0.02 | 0.78 | 0.74 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -1.39 | -1.18 | -1.16 | -1.03 | -0.84 | -1.30 | — | — |
| EV / EBITDA | -13.99 | -15.01 | -12.74 | -6.86 | -8.27 | — | — | — | — |
| EV / EBIT | -15.62 | -10.98 | -9.86 | -5.81 | -7.63 | — | — | — | — |
| EV / FCF | — | -24.76 | -21.33 | -7.10 | -0.81 | -133.41 | -3.34 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 67.9% | 67.9% | 69.4% | 70.8% | 70.1% | 69.9% | 68.7% | 61.5% | 50.1% |
| Operating Margin | 8.3% | 8.3% | 7.8% | 15.7% | 11.3% | -5.7% | -8.4% | -127.5% | -16.7% |
| Net Profit Margin | 11.8% | 11.8% | 10.7% | 17.8% | 11.1% | -3.9% | -7.0% | -126.0% | -13.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | 9.8% | 9.8% | 10.3% | 20.9% | 15.9% | -5.9% | -11.9% | — | — |
| ROA | 6.8% | 6.8% | 6.9% | 13.0% | 9.0% | -3.5% | -6.2% | -242.9% | -30.0% |
| ROIC | — | — | — | — | — | — | — | — | — |
| ROCE | 6.8% | 6.8% | 7.4% | 18.5% | 16.1% | -8.6% | -14.0% | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.02 | 0.00 | 0.01 | 0.06 | 0.01 | — | — |
| Debt / EBITDA | 0.15 | 0.15 | 0.17 | 0.02 | 0.07 | — | — | — | — |
| Net Debt / Equity | — | -1.15 | -1.15 | -1.26 | -1.35 | -1.35 | -1.33 | — | — |
| Net Debt / EBITDA | -15.31 | -15.31 | -12.95 | -7.05 | -8.50 | — | — | — | — |
| Debt / FCF | — | -25.26 | -21.69 | -7.31 | -0.84 | -138.44 | -4.13 | -2.61 | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($1.2B) exceeds total debt ($11M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.57 | 3.57 | 2.98 | 2.82 | 2.23 | 2.10 | 2.56 | 0.89 | 0.47 |
| Quick Ratio | 3.51 | 3.51 | 2.93 | 2.78 | 2.20 | 2.04 | 2.52 | 0.78 | 0.23 |
| Cash Ratio | 3.16 | 3.16 | 2.61 | 2.47 | 1.87 | 1.77 | 2.16 | 0.57 | 0.05 |
| Asset Turnover | — | 0.59 | 0.65 | 0.70 | 0.74 | 0.86 | 0.51 | 1.30 | 2.25 |
| Inventory Turnover | 12.12 | 12.12 | 12.01 | 17.97 | 15.39 | 10.13 | 9.87 | 4.07 | 2.22 |
| Days Sales Outstanding | — | 23.25 | 21.40 | 22.46 | 30.33 | 22.79 | 53.72 | 35.03 | 37.71 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 37.2% | 100.0% | 100.0% | — | — | — | 40.2% | — | — |
| Payout Ratio | 39.9% | 39.9% | 35.8% | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 91.5% | 416.7% | 532.5% | 537.5% | 390.4% | — | — | — | — |
| FCF Yield | 46.1% | 200.8% | 278.7% | 492.6% | 4434.8% | 19.9% | 126.2% | — | — |
| Buyback Yield | 17.1% | 74.4% | 52.5% | 28.4% | 24.8% | 0.5% | 0.0% | — | — |
| Total Shareholder Yield | 54.2% | 100.0% | 100.0% | 28.4% | 24.8% | 0.5% | 40.2% | — | — |
| Shares Outstanding | — | $11M | $11M | $11M | $11M | $11M | $9M | $11M | $11M |
Capital deployment and demographic headwinds
Based on reported figures, iHuman trades at a P/S ratio of 0.12 and a P/E of 1.09, suggesting that the market is heavily discounting the company's future growth potential and effectively valuing the firm as a liquidating entity rather than a going concern.
The extreme compression in valuation multiples relative to historical norms indicates that investors are placing little to no value on the company's core educational services. This pricing disconnect warrants further investigation into whether the market is overestimating the regulatory risk or if the current cash-heavy balance sheet is being viewed as trapped capital.
As reported in recent financial statements, iHuman's operating margin has contracted to 9.7% in 2025Q2 from 21.4% in 2023Q1, highlighting a failure to maintain operating leverage as the company struggles to offset declining revenue with cost-cutting measures.
While the gross margin remains robust at 67.8%, the significant drop in operating profitability suggests that fixed costs, particularly in content development and marketing, are becoming increasingly burdensome. Investors should monitor whether management can stabilize these margins or if the current cost structure is fundamentally misaligned with the shrinking addressable market.
According to recent financial data, iHuman's ROE has fluctuated significantly, dropping from 6.8% in 2023Q1 to 3.3% in 2025Q2, which indicates a diminishing ability to generate meaningful returns on equity as the company's core business model faces persistent top-line headwinds.
The decline in return metrics appears to be driven by the combination of revenue contraction and the accumulation of idle cash on the balance sheet, which dilutes overall capital efficiency. This trend suggests that the company is currently failing to compound shareholder value effectively, necessitating a strategic pivot or more aggressive capital allocation.
Based on the latest quarterly filings, iHuman's cash conversion cycle remains relatively stable at 23 days, suggesting that the company maintains efficient control over its inventory and receivables despite the broader challenges facing its educational product segment.
The consistency in DSO and DIO metrics indicates that the company's operational processes are not currently suffering from the same deterioration as its top-line growth. However, this efficiency may be masking underlying demand issues, as the company may be clearing inventory at the expense of future growth potential.
The P/E ratio is frequently misapplied to iHuman's business model, as it fails to account for the massive cash-to-market-cap disparity that distorts earnings-based valuation multiples and obscures the company's true operational health.
Because iHuman holds a significant cash position relative to its market capitalization, the P/E ratio provides a misleading picture of the company's profitability. Analysts should instead utilize an EV/EBITDA metric or a cash-adjusted P/E to better understand the underlying earning power of the core business, excluding the impact of interest income.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying IH stock.
iHuman Inc.'s current P/E ratio is 1.1x. The historical average is 0.2x. This places it at the 100th percentile of its historical range.
iHuman Inc.'s current EV/EBITDA is -14.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.
iHuman Inc.'s return on equity (ROE) is 9.8%. The historical average is 6.5%.
Based on historical data, iHuman Inc. is trading at a P/E of 1.1x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
iHuman Inc.'s current dividend yield is 37.16% with a payout ratio of 39.9%.
iHuman Inc. has 67.9% gross margin and 8.3% operating margin.
iHuman Inc.'s Debt/EBITDA ratio is 0.2x, indicating low leverage. A ratio below 2x is generally considered financially healthy.